Ghori, Razi
https://orcid.org/0009-0004-3095-8612
Mayo Clinic
Merck & Co., Inc., Rahway, NJ, USA (United States)
Citations 3
P628: UPDATED ANALYSIS OF BELLWAVE-001: A PHASE 1/2 OPEN-LABEL DOSE-EXPANSION STUDY OF THE EFFICACY AND SAFETY OF NEMTABRUTINIB FOR THE TREATMENT OF B-CELL MALIGNANCIES
Woyach, Jennifer A. , Eradat, Herbert, Brander, Danielle M. , Tees, Michael, Ghori, Razi , Farooqui, Mohammed, Flinn, Ian W. , Awan, Farrukh T. , Parikh, Sameer A. , Phillips, Tycel , Paydar, Ima , Byrd, John C. , Stephens, Deborah M.
HemaSphere | August 21, 2023 | Volume: 7 | Issue: S3 | Pages: e7809236
Updated follow‐up of BELLWAVE‐001: an open‐label, single‐arm, phase 1/2 study of the efficacy and safety of nemtabrutinib for the treatment of B‐cell malignancies
Eradat, Herbert, Woyach, Jennifer A. , Brander, Danielle M. , Tees, Michael, Ghori, Razi , Farooqui, Mohammed Z.H. , Byrd, John C. , Flinn, Ian W. , Awan, Farrukh T. , Parikh, Sameer A. , Phillips, Tycel , Paydar, Ima , Stephens, Deborah M.
Hematological Oncology | June 9, 2023 | Volume: 41 | Issue: S2 | Pages: 565-567
Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study
Woyach, Jennifer A. , Eradat, Herbert, Brander, Danielle M. , Tees, Michael, Ghori, Razi , Reddy, Nishitha , Farooqui, Mohammed Z.H. , Byrd, John C. , Byrd, John C , Flinn, Ian W. , Awan, Farrukh T. , Parikh, Sameer A. , Phillips, Tycel , Stephens, Deborah M.
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 7004-7006